findmyKOL

Alan Fleischer, MD

Enriched profile

Professor of Clinical Dermatology; Residency Program Director · University of Cincinnati College of Medicine

ORCIDNPI
Region🇺🇸 Cincinnati, OH · Midwest · United StatesSpecialtyDermatologyFocusAtopic Dermatitis / Eczema+2
Active KOLfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publicationSee ScholarshipOnline presenceverified 2026Payments2021–2025NIH fundingNone on fileWhy? →

Alan Fleischer is Professor of Clinical Dermatology; Residency Program Director at University of Cincinnati College of Medicine. OpenAlex indexes 486 publications with 18,355 citations (h-index 69); ClinicalTrials.gov lists 12 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 5% of Dermatology profiles in the findmyKOL directory.

Data verified 14 Aug 2026

Overview

Updated 27 Aug 2026

Alan B. Fleischer Jr., MD, is Professor of Clinical Dermatology at University of Cincinnati College of Medicine / UC Health, Department of Dermatology. The public record shows 486 publications with 18,355 citations (h-index 69), centered on Atopic Dermatitis / Eczema, Acne / Hidradenitis, Psoriasis (Derm). It also documents an investigator role on 12 registered clinical trials, industry payments reported by 10 companies.

  • Top research focus: Atopic Dermatitis / Eczema
  • 12 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 10 companies

Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Tinea3 trialsAtopic Dermatitis / Eczema2 trialsAcne / Hidradenitis2 trialsAcne Vulgaris2 trialsLymphoma1 trialLymphoma, T-Cell, Cutaneous1 trialLymphoma, T-Cell1 trialPruritus1 trialSkin Diseases1 trialHand Dermatoses1 trialPsoriasis / Psoriatic Arthritis1 trialPsoriasis (Derm)1 trialTinea Pedis1 trialTinea Cruris1 trialRosacea1 trial

Research focus

OpenAlex concept fingerprint
Atopic Dermatitis / EczemaAcne / HidradenitisPsoriasis (Derm)

Drugs & molecules

across trials, industry payments and publications
Cosentyxgeneric · SecukinumabClinical trialsIndustry payments4PublicationsTaltzgeneric · IxekizumabClinical trialsIndustry payments3PublicationsDupixentgeneric · DupilumabClinical trialsIndustry payments2Publications

Works with

trial sponsors and companies reporting payments
Incyte CorporationClinical trialsIndustry payments5Novartis Pharmaceuticals CorporationClinical trialsIndustry payments5Wake Forest UniversityClinical trials5Industry payments

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
486publications

Distinct works indexed by OpenAlex, matched via ORCID; 4 in PubMed.

18,355citations

Total citations across indexed works.

69h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
12clinical trials

Investigator role on registered studies.

View trials
10companies · 2021–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments
0NIH grants

Federally funded research awards.

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 27 Aug 2026

Listed as an investigator on 12 registered studies on ClinicalTrials.gov. The most recent:

Industry payments

Updated 27 Aug 2026

10 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cancer & immunology

    26.6%
    TNF inhibitor11.5%
    Humira(Cf) Pen100%
    Part D11 patients
    Nucleoside Metabolic Inhibitor4.2%
    Fluorouracil100%
    Part D29 patients
  • Dermatology

    25.9%
    Interleukin-4 Receptor alpha Antagonist13.6%
    Dupixent Pen82%Dupixent Syringe18%
    Part D<11 patients
    Corticosteroid10.4%
    Triamcinolone Acetonide100%
    Part D62 patients
  • Anti-infectives

    20.3%
    Tetracycline-class Drug8.3%
    Doxycycline Monohydrate46%Doxycycline Hyclate40%Minocycline Hcl15%
    Part D<11 patients
    Azole Antifungal3.3%
    Ketoconazole100%
    Part D17 patients
5 more therapeutic areas behind the reveal.Reveal →
Where care is delivered (Part B)1.2% facility · 98.8% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →

Publications

None on file yet. We only list publications we can confidently match to this person. Why? →

Online presence

Updated 27 Aug 2026

This person's own public accounts first, then places where others mention them. Two different things, listed separately.

Owned accounts

public accounts run by this person
  • Doximity

    doximity.com/pub/alan-fleischer-md-ffedddda

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com
  • ResearchGate

    researchgate.net/profile/Alan-Fleischer

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net

Mentions by others

where others cite or feature them
  • Other

    sciprofiles.com/profile/2752916

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →sciprofiles.com
  • LinkedIn

    LinkedIn: Alan Fleischer - Professor and Residency Program Director - University of Cincinnati College of Medicine

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com

We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.

Background & recognition

Updated 27 Aug 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record
  • Board Certified

    American Board of Dermatology

    2026
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →med.uc.edu
  • Residency in Dermatology

    University of North Carolina at Chapel Hill

    1991
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uchealth.com
  • MD

    University of Missouri-Columbia

    1987
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uchealth.com
  • BA

    University of Missouri-Columbia

    1982
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uchealth.com

Editorial & leadership roles

journal and society appointments
  • Director

    Department of Dermatology, University of Cincinnati College of Medicine

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →med.uc.edu
  • Residency Program Director

    Dermatology, University of Cincinnati College of Medicine

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →med.uc.edu

Awards & honors

honors on the public record

Media & interviews

press, podcasts and appearances

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.